MN-DIGI-INTERNATIONAL
Digi International, (NASDAQ: DGII, www.digi.com ), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, today extended its IoT solution portfolio with the unveiling of its new Digi ConnectCore® MP1 family of system-on-modules (SOMs). The MP1 is the industry’s smallest STM32MP1 SOM that integrates Wi-Fi, Bluetooth and wired connectivity without comprising design flexibility.
This solution is made complete with its Connected Device platform as well as its well-tested development tools and design support. This makes Digi ConnectCore MP1 SOMs a cost-effective wireless solution for original equipment manufacturers (OEMs) seeking to reduce risk and effort in their product development. Ideal Digi ConnectCore MP1 applications include handheld products with cameras and/or displays such as medical devices, environmental test equipment, industrial human machine interfaces, or headless devices such as EV charging stations, renewable-energy controllers and others.
Leveraging both new and market-proven STM32MP1 micro processing units (MPUs) from STMicroelectronics (STM), Digi ConnectCore MP1 SOMs offer more features with a lower total cost of ownership. The form factor is smaller than a postage stamp (29x29 mm), which is ideal for form-factor-challenged applications with low-profile requirements. These off-the-shelf family of Digi ConnectCore MP1 SOMs bring scalability, compatibility and pre-certified wireless connectivity in a solution suitable for a broad range of applications in the healthcare, transportation and industrial sectors.
The unique Digi SMTplus™ surface-mount form factor provides design flexibility by enabling more complex applications through land grid array (LGA) pads and less complex applications using edge-castellated pads. By eliminating the need for connectors, ConnectCore SOMs shrink the bill of materials and offer greater suitability for high-vibration and harsh environment applications where connectors are prohibitive.
Small Form Factor Packed with High-Performance Features
- STM32MP15x, single/dual Cortex-A7 @ 650 MHz
- Cortex-M4 companion processing core for real-time tasks (STM32MP15x only)
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.0 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity (single 10/100/1000 Eth for STM32MP15x)
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework – ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“Digi ConnectCore MP1 SOMs respond to the challenge of building intelligent, connected and secure wireless products in strongly regulated markets such as the healthcare, transportation, and industrial sectors,” said Andreas Burghart, Senior Product Manager with Digi. “Unlike other SOMs, Digi ConnectCore MP1 provides a scalable, highly integrated solution that encompasses a complete set of development tools, design support, software, and security building blocks to accelerate time to market. Digi also provides remote management and security services to simplify deployment and ongoing maintenance throughout the entire product lifecycle.”
For more information, visit https://www.digi.com/ccmp1 .
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit www.digi.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005044/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom